Scarica l'app Stockscreener
11.61
7.64%
-0.96
Dopo l'orario di chiusura:
11.50
-0.11
-0.95%
Precedente Chiudi:
$12.57
Aprire:
$11.01
Volume 24 ore:
666.80K
Relative Volume:
1.48
Capitalizzazione di mercato:
$35.13M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+128.94%
1M Prestazione:
+160.05%
6M Prestazione:
+2.97%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$9.71
$12.25
Intervallo di 1 settimana:
$5.00
$19.44
Portata 52W:
$4.06
$19.44
Traws Pharma Inc Stock (TRAW) Company Profile
Nome
Traws Pharma Inc
Settore
Industria
Telefono
267-759-3680
Indirizzo
12 PENNS TRAIL, NEWTOWN
Confronta TRAW con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
11.61 | 35.13M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.18 | 105.12B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
714.47 | 78.51B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
629.99 | 37.67B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.25 | 31.37B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
114.13 | 27.36B | 3.30B | -501.07M | 1.03B | -2.1146 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-03-01 | Iniziato | Ladenburg Thalmann | Buy |
| 2021-05-18 | Iniziato | Guggenheim | Buy |
| 2018-03-01 | Reiterato | H.C. Wainwright | Buy |
| 2018-01-17 | Downgrade | Maxim Group | Buy → Hold |
| 2017-10-09 | Iniziato | H.C. Wainwright | Buy |
| 2017-04-27 | Iniziato | Laidlaw | Buy |
| 2015-07-01 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2015-05-05 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Traws Pharma Inc Borsa (TRAW) Ultime notizie
Traws Pharma, Inc. Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird Flu - Marketscreener.com
Nasdaq Surges Over 100 Points, US Durable Goods Orders Decline In November - Benzinga
Traws Pharma Stock Rockets On Promising H5N1 Bird Flu Treatment Results - Benzinga
Stock market news: Direct Digital Holdings +405.45%, Reliance Global Group +214.17% among top gainers during mid day trading - Business Upturn
Stock market news: Direct Digital Holdings up by 363.64% while iLearningEngines down by 70.88% during mid day trading - Business Upturn
Traws Pharma Stock Hits 6-Month Highs On Bird Flu Treatment Breakthrough, Retail Interest Soars - Asianet Newsable
Key pre-market developments in biotech & aerospace - RagingBull
Stock market today: Traws Pharma +231.47%, Rumble +59.02% among top gainers in early trading - Business Upturn
US Stocks Mixed, Dow Tumbles 150 Points - Benzinga
Stock market today: iLearningEngines plunges by 60.44% while Reliance Global Group surged by 231.67% in early trading session - Business Upturn
Traws Pharma Shares Surge 83% on Development of Bird Flu Treatment - MarketWatch
Traws Pharma advances bird flu treatment candidate - Investing.com
Traws Pharma's Bird Flu Drug Shows Breakthrough Results in Phase 1 Trial, Achieves 23-Day Protection - StockTitan
The Most Therapeutic Kind of Me-Time - 69News WFMZ-TV
Traws Pharma announces board member departure By Investing.com - Investing.com Australia
Traws Pharma announces board member departure - Investing.com
Antibiotics Do Not Increase Risks for Cognitive Decline, Dementia in Older Adults, New Data Says - 69News WFMZ-TV
More of America's Pets Are Overdosing on Stray Coke, Meth - 69News WFMZ-TV
Trinity Capital Commits $50M to Form Energy's Revolutionary Iron-Air Battery Manufacturing - StockTitan
Full Stock Market News from 2024-12-14 - StockTitan
Traws Pharma faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Canada
Traws Pharma faces Nasdaq delisting over equity shortfall - Investing.com
Onconova Therapeutics stock hits 52-week low at $4.37 - Investing.com India
Traws Pharma Faces Uncertain Future Amid Complex Onconova Merger - MSN
Onconova Therapeutics stock hits 52-week low at $4.37 By Investing.com - Investing.com Australia
Onconova Therapeutics, Inc. Announces Management Changes - Marketscreener.com
Traws Pharma Reports Q3 Financials and Updates on Clinical Advances - MSN
Traws Pharma (FRA:0T20) 3-Year EPS without NRI Growth Rate : 25.30% (As of Sep. 2024) - GuruFocus.com
Traws Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Traws Pharma Inc (TRAW) Quarterly 10-Q Report - Quartzy
Traws Pharma Reports Promising Antiviral Drug Progress - TipRanks
Traws Pharma earnings missed by $8.56, revenue topped estimates - Investing.com Canada
Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results - The Manila Times
Traws Pharma Reports Promising Phase 1 Data Despite Widening Q3 Losses | TRAW Stock News - StockTitan
Onconova Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update - Marketscreener.com
Traws Pharma regains Nasdaq compliance with bid price - Investing.com India
Traws Pharma regains Nasdaq compliance with bid price By Investing.com - Investing.com UK
Expert Systems Celebrates Milestone in Clinical Development of Tivoxavir Marboxil, Potential One-Time Influenza Treatment - StockTitan
Traws Pharma Inc (TRAW) Q2 2024 Earnings Call Highlights: Navigating Financial Challenges Amid ... - Yahoo Finance
Traws Pharma Reports Positive Phase 1 Results for Influenza Therapy Tivoxavir Marboxil - MyChesCo
Onconova Therapeutics stock hits 52-week low at $4.87 - Investing.com India
Traws Pharma reports positive Phase 1 flu drug results - Investing.com
Traws Pharma reports positive Phase 1 flu drug results By Investing.com - Investing.com Canada
Traws Pharma announces topline Phase 1 data for tivoxavir marboxil - TipRanks
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil - GlobeNewswire
Traws Pharma, Inc. Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil - Marketscreener.com
Onconova Therapeutics stock hits 52-week low at $4.87 By Investing.com - Investing.com Australia
Traws Pharma Inc Azioni (TRAW) Dati Finanziari
Non sono disponibili dati finanziari per Traws Pharma Inc (TRAW). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.10%
0.76%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):